Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health | FMCG | Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Terry on +44 1494 818004 or terry@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Terry Crystal
Recruitment Consultant
terry@zenopa.com
+44 1494 818004

Testimonials
I have been working through a contract with Zenopa since March 2012. I actually find this approach more beneficial to me as I have someone independent from the company who I can talk to about any issu...
Jennifer, 2012

Ark Therapeutics highlights business progress in 2011 year to date

20 May 2011 00:00 in Medical Company Financials


Ark Therapeutics has published its interim management statement for the year to date, expressing satisfaction with the development of its business during the period.

During the opening months of 2011, the medical technology firm has been able to complete the sale of the majority of its woundcare business to Crawford Healthcare, meeting one of the key goals of its September 2010 strategic restructuring plan.

The period has also seen the firm experience increased interest in the use of its bio-manufacturing facility in Kuopio, Finland, an asset that the company is keen to exploit more fully.

Meanwhile, progress is also being made in the development of various products in its pipeline, while several key executive appointments have been made.

Martyn Williams, chief executive officer of Ark, said: "We have seen real progress across all our activities and believe we are well-placed to deliver on the remaining objectives we have set ourselves for this year."

This comes in the same month that the company held its annual general meeting, during which all resolutions being voted on were passed.ADNFCR-8000103-ID-800551303-ADNFCR

Other news stories from 20/05/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Adfero News Agency



   
© Copyright 2013 Zenopa Ltd